Were pleased to announce our plans for developing LB-001 in pediatric patients with MMA.
- Were pleased to announce our plans for developing LB-001 in pediatric patients with MMA.
- Early intervention in this vulnerable population is critical to combat the manifestation of irreversible clinical disease pathologies including neurological damage.
- Six leading centers in the United States are expected to participate in the SUNRISE Phase 1/2 trial.
- LogicBio has received FDA clearance for the first-in-human clinical trial of LB-001, a wholly owned genome editing program leveraging GeneRide for the treatment of methylmalonic acidemia.